Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-212,522
Closed -$7.5M 3851
2023
Q3
$7.5M Buy
212,522
+6
+0% +$229 ﹤0.01% 1954
2023
Q2
$8.08M Buy
212,516
+9,442
+5% +$376K ﹤0.01% 1961
2023
Q1
$7.67M Sell
203,074
-68,072
-25% -$2.62M ﹤0.01% 1995
2022
Q4
$11.5M Buy
271,146
+7,658
+3% +$316K ﹤0.01% 1755
2022
Q3
$8.47M Sell
263,488
-182
-0.1% -$6.39K ﹤0.01% 1904
2022
Q2
$8.57M Sell
263,670
-42,854
-14% -$1.39M ﹤0.01% 1957
2022
Q1
$11.1M Sell
306,524
-44,756
-13% -$1.54M ﹤0.01% 1906
2021
Q4
$13.9M Buy
351,280
+8
+0% +$334 ﹤0.01% 1794
2021
Q3
$15.3M Buy
351,272
+6,449
+2% +$290K ﹤0.01% 1734
2021
Q2
$14.1M Sell
344,823
-104,114
-23% -$4.02M ﹤0.01% 1842
2021
Q1
$14.7M Buy
448,937
+168,910
+60% +$6.35M ﹤0.01% 1726
2020
Q4
$11.4M Buy
+280,027
New +$10.5M ﹤0.01% 1729

Other funds holding GMAB

Invesco's GMAB Position: Q4 2023 in Review

Invesco sold out of Genmab (GMAB) in Q4 2023, closing a stake of 212,522 shares — an estimated $7.5M sold.

Invesco first reported a position in GMAB in Q4 2020 and held it in 12 quarters. The position peaked at $15.3M in Q3 2021. 225 funds tracked by Wall St. Rank hold GMAB as of Q4 2023.

  • Invesco reported no remaining Genmab position as of Q4 2023 after selling out during the quarter.
  • Invesco sold 212,522 Genmab shares in Q4 2023, an estimated $7.5M.
  • Invesco first reported a position in Genmab in Q4 2020 and held it in 12 quarters.
  • Invesco's Genmab position peaked at $15.3M in Q3 2021.
  • 225 funds tracked by Wall St. Rank held Genmab as of Q4 2023.

Based on Invesco's 13F filing for Q4 2023, filed 13 Feb 2024.